Drug Approval | January 03, 2024
Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
The company has received five final approvals
The company has received five final approvals
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Prior to joining Alembic, he was working with Lupin Limited for more than 11 years
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Lincoln Pharmaceuticals has reported total income of Rs. 164.68 crores during the period ended September 30, 2023
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Subscribe To Our Newsletter & Stay Updated
